Gland Pharma Ltd.'s net profit for the fourth quarter of fiscal 2026 rосkеted 97% year-on-year, according to an exchange filing on Friday
The Pharma giant posted a consolidated bottom-line of Rs 3.666.75 crore, compared to Rs 1,865.41 crore in the year ago period
The company has also declared a dividend of Rs 20 per share of Rs 1 each for the financial year 2025-26. To determine the eligibility of shareholders, Gland Pharma has set August 11, 2026 as the record date.
"The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the 48th Annual General Meeting (AGM), the filing stated
Topline for the pharma company came in at Rs 17,427.9 crore, up 22.3% from Rs 14.249.09 crore in the corresponding period of the last fiscal
Earnings before interest, taxes, depreciation, and amortisation rose 48% to Rs 513 crore from Rs 347 crore in the year-ago period. On the operational front, Ebitda margin expanded to 29.4% from 24.4% in Q4 of FY25.
Follow all the LIVE earnings updates here.
Gland Pharma Q4 Result Highlights (Cons, YoY)
- Net Profit rises 97% to Rs 3,666 75 crore versus Rs 1,865 41 crore.
- Revenue rises 22.3% to Rs 17,427.9 crore versus-25 14.249 09 crore.
- Ebitda rises 48% to Rs 5,130.20 crore versus Rs 3475.20 crore
- Margin at 29.4% versus 24.4%
Gland Pharma Share
Gland Pharma's shares closed 1.6% lower at Rs 1,868.30 apiece on the NSE on Friday. This compared to a 0.19% decline in the benchmark Nifty index.
The stock has risen 8.5% year-to-date and 27.94% in the last 12 months.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.